AR052191A1 - Metodo de tratamiento - Google Patents
Metodo de tratamientoInfo
- Publication number
- AR052191A1 AR052191A1 ARP060100058A ARP060100058A AR052191A1 AR 052191 A1 AR052191 A1 AR 052191A1 AR P060100058 A ARP060100058 A AR P060100058A AR P060100058 A ARP060100058 A AR P060100058A AR 052191 A1 AR052191 A1 AR 052191A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- related disorders
- substance
- pharmaceutically acceptable
- limited
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000011117 substance-related disease Diseases 0.000 abstract 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 abstract 2
- 229950010883 phencyclidine Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 abstract 1
- 208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000003863 Marijuana Abuse Diseases 0.000 abstract 1
- 208000026251 Opioid-Related disease Diseases 0.000 abstract 1
- 231100000643 Substance intoxication Toxicity 0.000 abstract 1
- 208000028505 alcohol-related disease Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 229940005530 anxiolytics Drugs 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000035548 disruptive behavior disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003326 hypnotic agent Substances 0.000 abstract 1
- 230000000147 hypnotic effect Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 201000006152 substance dependence Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Un método para tratar al menos un síntoma o afeccion asociado con, aunque sin limitarse a: 1) Trastornos relacionados con sustancias incluyendo aunque sin limitarse a Dependencia de Sustancias, Abuso de Sustancias, Intoxicacion por Sustancias, Abstinencia de Sustancias, Trastornos Relacionados con el Alcohol, Trastornos Relacionados con Anfetaminas ( o Tipo Anfetaminas), Trastornos Relacionados con la Cafeína, Trastornos Relacionados con el Cannabis, Trastornos Relacionados con la Cocaína, Trastornos Relacionados con Alucinogenos, Trastornos relacionados con Inhalantes, Trastornos relacionados con la Nicotina, Trastornos relacionados con Opioides, Trastornos relacionados con Fenciclidina ( o del Tipo de la Fenciclidina) y Trastornos relacionados con Sedantes, Hipnoticos o Ansiolíticos; 2) Trastornos de Déficit de Atencion y Comportamiento Disruptivo; 3) Trastornos de la Alimentacion; 4) Trastornos de Personalidad que incluyen, aunque sin limitarse a Trastorno de la Personalidad Obsesivo-Compulsivo; 5) Trastornos de Control de Impulsos, que comprende la administracion de una cantidad eficaz de formula (1) o su sal farmacéuticamente aceptable. En otro aspecto de la presente se proporciona una composicion farmacéutica que comprende una cantidad eficaz de formula (1) o su sal farmacéuticamente aceptable y por lo menos un portador o diluyente farmacéuticamente aceptable.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64226205P | 2005-01-07 | 2005-01-07 | |
| US73786505P | 2005-11-18 | 2005-11-18 | |
| US73786405P | 2005-11-18 | 2005-11-18 | |
| US73788705P | 2005-11-18 | 2005-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052191A1 true AR052191A1 (es) | 2007-03-07 |
Family
ID=36647771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100058A AR052191A1 (es) | 2005-01-07 | 2006-01-06 | Metodo de tratamiento |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1838325A1 (es) |
| JP (1) | JP2008526839A (es) |
| AR (1) | AR052191A1 (es) |
| TW (1) | TW200640466A (es) |
| UY (1) | UY29326A1 (es) |
| WO (1) | WO2006073360A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007062339A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| RS52703B (sr) * | 2008-06-20 | 2013-08-30 | Astrazeneca Ab | Derivat dibenzotiazepina i njegova upotreba |
| US8389716B2 (en) | 2009-01-30 | 2013-03-05 | F.I.S. Fabbrica Italiana Sintetici S.P.A. | Process for the synthesis of quetiapine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US7071133B2 (en) * | 1993-11-16 | 2006-07-04 | Ppg Industries Ohio, Inc. | Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift |
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| SE0003126D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Method of treatment |
| ES2284830T3 (es) * | 2001-02-06 | 2007-11-16 | Astrazeneca Ab | Uso de quetiapina para el tratamiento de la cocaina. |
| WO2004034996A2 (en) * | 2002-10-18 | 2004-04-29 | Massachusetts Mental Health Institute | TREATING ALCOHOL AND OR SUBSTANCE ABUSE BY ANTAGONIZING α 2 ADRENERGIC RECEPTORS WITH WEAK DOPAMINE BLOCKING |
| EP1644005B1 (en) * | 2003-07-02 | 2010-08-18 | AstraZeneca AB | Metabolite of quetiapine |
| CA2547652A1 (en) * | 2003-12-04 | 2005-06-16 | The Research Foundation Of The City University Of New York | Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal |
| ATE426405T1 (de) * | 2003-12-22 | 2009-04-15 | Acadia Pharm Inc | Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
-
2006
- 2006-01-04 JP JP2007550327A patent/JP2008526839A/ja active Pending
- 2006-01-04 WO PCT/SE2006/000009 patent/WO2006073360A1/en not_active Ceased
- 2006-01-04 EP EP06700349A patent/EP1838325A1/en not_active Withdrawn
- 2006-01-05 UY UY29326A patent/UY29326A1/es not_active Application Discontinuation
- 2006-01-06 TW TW095100687A patent/TW200640466A/zh unknown
- 2006-01-06 AR ARP060100058A patent/AR052191A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY29326A1 (es) | 2006-08-31 |
| EP1838325A1 (en) | 2007-10-03 |
| WO2006073360A1 (en) | 2006-07-13 |
| TW200640466A (en) | 2006-12-01 |
| JP2008526839A (ja) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serretti et al. | New antipsychotics and schizophrenia: a review on efficacy and side effects | |
| Bhutada et al. | Reversal by quercetin of corticotrophin releasing factor induced anxiety-and depression-like effect in mice | |
| BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
| BRPI0607017B8 (pt) | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc | |
| BRPI0519181A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, mÉtodos para produzir um efeito inibitàrio de b-raf em um animal de sangue quente, para produzir um efeito anti-cÂncer em um animal de sangue quente e para tratar uma doenÇa em um animal de sangue quente | |
| EP1478371A4 (en) | METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS | |
| BR0317358A (pt) | Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso | |
| AR055095A1 (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c | |
| BRPI0411906A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos | |
| BRPI0414428A (pt) | composições farmacêuticas | |
| WO2001066123A3 (en) | Composition consisting of phy906 and chemotherapeutic agents | |
| UY30659A1 (es) | Grupo de compuestos de benzoilamino heterociclico, composiciones farmacéuticas, porcesos para su preparacion y aplicaciones. | |
| AR062068A1 (es) | Sal tartrato de(7)s-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-metilpiperazin-il]-6,7-dihidro-5h-ciclopenta[b]piridina, composiciones farmaceuticas que la contienen, y usos en trastornos asociados fundamentalmente al scn | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
| Yu et al. | Synergic effect of borneol and ligustrazine on the neuroprotection in global cerebral ischemia/reperfusion injury: A region‐specificity study | |
| Zeni et al. | Antidepressant-like and neuroprotective effects of Aloysia gratissima: investigation of involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway | |
| Martin | Therapeutic potential of KELEA activated water | |
| BRPI0511874A (pt) | derivados da pirrolopiridina | |
| Devi | Milk thistle (Silybum marianum) | |
| ATE410424T1 (de) | Spirocyclische cyclohexan-derivate | |
| BRPI0409796A (pt) | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina | |
| FI20095600A7 (fi) | Koostumus ihosairauksien hoitoa varten | |
| Takeuchi et al. | Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr‐Abl positive leukemic cells | |
| Ebrahimzadeh et al. | Anticonvulsant activity of Hypericum scabrum L.; possible mechanism involved |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |